Congress did not pass SALSA, however, choosing instead to pass a series of one-year delays to PAMA implementation. Some in the industry have suggested the bill struggled in part due to the complexity of its statistical sampling-based approach as well as its continued reliance on lab-reported price data. Over the last year, stakeholders including the American Clinical Laboratory Association (ACLA) and the College of American Pathologists (CAP) have indicated they were exploring alternative legislative approaches to PAMA reform.
For the full article click here: Congress Introduces New Legislation to Reform Protecting Access to Medicare Act